Skip to main content
PepStack

FGF-21

Growth Factors
Fibroblast Growth Factor 21FGF21

Overview

Fibroblast Growth Factor 21 (FGF-21) is an endogenous hormone primarily produced in the liver, with additional expression in adipose tissue and the pancreas. It belongs to the fibroblast growth factor family, which is a group of proteins involved in a variety of biological processes. FGF-21 is a peptide hormone that plays a significant role in regulating metabolism and energy homeostasis. Researchers have been investigating both its natural functions and potential therapeutic applications.

FGF-21 is primarily involved in the regulation of glucose and lipid metabolism. It has been shown to enhance insulin sensitivity, promote weight loss, and improve lipid profiles in animal models. Research areas include its potential role in treating metabolic disorders such as obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD). Researchers have also explored its effects on longevity and cardiovascular health.

The mechanism of action of FGF-21 involves binding to the FGF receptor complex, which requires the co-receptor β-Klotho for activation. This interaction triggers downstream signaling pathways, including the MAPK/ERK and PI3K/AKT pathways, leading to various metabolic effects. These pathways are crucial for the hormone's role in regulating glucose uptake and lipid metabolism.

Pharmacokinetic properties of FGF-21 include a relatively short circulating half-life, with researchers observing rapid clearance from the bloodstream. The hormone is primarily metabolized in the liver, and its bioavailability can vary depending on the route of administration. Subcutaneous administration has been studied for its potential therapeutic use, although detailed pharmacokinetic data are limited.

Clinically, FGF-21 is not yet approved for therapeutic use, but it is under investigation in clinical trials for its potential benefits in metabolic diseases. Regulatory standing varies by region, and it is not currently available as a prescription medication. Researchers continue to explore its clinical applications and potential regulatory approval in the future.

Mechanism of Action

FGF-21 acts on the FGF receptor complex, requiring the co-receptor β-Klotho for activation. This interaction activates the MAPK/ERK and PI3K/AKT signaling pathways, leading to enhanced insulin sensitivity and improved lipid metabolism.

Half-Life & Pharmacokinetics

EndogenousCirculating half-life ~0.5-2 hours
OralPoor bioavailability due to first-pass metabolism

Pharmacokinetic data for synthetic forms are limited; variations may exist based on formulation.

Storage

Temperature

Refrigerate at 2-8°C

Light

Protect from light

Form

Aqueous solution: use within specified period post-reconstitution

Notes

Ensure proper storage conditions to maintain stability and efficacy.

Solubility

FGF-21 is soluble in water, which is relevant for its formulation as an injectable solution.

Legal Status

🇩🇪DE

Data limited

🇺🇸US

Not FDA approved; under investigation in clinical trials

🇦🇺AU

Data limited

🇬🇧UK

Data limited

Legal status information is provided for general reference only and may not reflect the most current regulatory changes. Always verify with official government sources before making any decisions.

10 Research Publications

Fibroblast growth factor 21.

Review

Differentiation; research in biological diversity · 2024

Researchers observed that Fibroblast Growth Factor 21 (FGF21) is an important hormone involved in various bodily functions, including metabolism and immunity. They found that FGF21 levels are linked to conditions like obesity and diabetes, and that manipulating FGF21 levels in animal models can affect weight and immune responses. This hormone is being explored for potential therapies to treat liver diseases related to metabolic issues.

  • FGF21 plays a role in metabolism, reproduction, and immunity.
  • Higher FGF21 levels are associated with obesity, type 2 diabetes, and other diseases.
  • FGF21-based therapies are being developed for liver disease treatment.
PubMed

Fibroblast growth factor-21 is required for weight loss induced by the glucagon-like peptide-1 receptor agonist liraglutide in male mice fed high carbohydrate diets.

Animal

Molecular metabolism · 2023

Researchers found that the drug liraglutide helps promote weight loss in male mice by increasing levels of a protein called FGF21. They observed that this effect is particularly important when the mice are fed high carbohydrate diets, as the absence of FGF21 in the liver makes it harder for liraglutide to reduce food intake and promote weight loss.

  • Liraglutide increases FGF21 levels independently of food intake.
  • Mice lacking liver FGF21 do not lose weight effectively with liraglutide.
  • The interaction between GLP-1R and FGF21 is crucial for weight management on high carbohydrate diets.
PubMed

Fibroblast growth factor 21 attenuates ventilator-induced lung injury by inhibiting the NLRP3/caspase-1/GSDMD pyroptotic pathway.

Human

Critical care (London, England) · 2023

Researchers found that higher levels of fibroblast growth factor 21 (FGF21) in patients and mice undergoing mechanical ventilation are linked to lung injury. They observed that FGF21 helps protect against this injury by inhibiting a specific inflammatory pathway. This suggests that increasing FGF21 levels could be a potential treatment for lung injury in critically ill patients.

  • Higher serum FGF21 levels are associated with increased lung injury during mechanical ventilation.
  • FGF21-deficient mice experienced worse lung injury compared to normal mice.
  • Administering FGF21 reduced lung injury and inflammation in both mouse and cell models.
PubMed

Targeting FGF21 in cardiovascular and metabolic diseases: from mechanism to medicine.

Review

International journal of biological sciences · 2023

Researchers observed that fibroblast growth factor 21 (FGF21) plays a significant role in cardiovascular and metabolic diseases, such as heart disease and diabetes. They highlighted new potential drug targets related to FGF21 that could lead to better treatments for these conditions.

  • FGF21 is linked to various cardiovascular and metabolic diseases.
  • New molecular targets related to FGF21 could improve treatment options.
  • There is ongoing research into developing effective FGF21-based drugs.
PubMed

Sulforaphane ameliorates non-alcoholic fatty liver disease in mice by promoting FGF21/FGFR1 signaling pathway.

Animal

Acta pharmacologica Sinica · 2022

Researchers found that sulforaphane (SFN), a compound found in certain vegetables, improved liver health in mice with non-alcoholic fatty liver disease (NAFLD). They observed that SFN works by enhancing a specific signaling pathway involving FGF21, which helps regulate fat metabolism in the liver.

  • SFN reduced liver fat and inflammation in mice with NAFLD.
  • SFN increased levels of FGF21 and its receptor, FGFR1, in the liver.
  • Combining SFN with FGF21 further improved liver health in NAFLD mice.
PubMed

Hepatocyte-specific fibroblast growth factor 21 overexpression ameliorates high-fat diet-induced obesity and liver steatosis in mice.

Animal

Laboratory investigation; a journal of technical methods and pathology · 2022

Researchers observed that increasing levels of a protein called FGF21 in the liver of mice on a high-fat diet led to significant weight loss and improved liver health. This protein helped the body better process fats and reduced fat buildup in the liver, suggesting it could be a potential target for treating obesity-related liver issues.

  • FGF21 overexpression reduced body weight and fat mass in mice on a high-fat diet.
  • The treatment improved insulin sensitivity and decreased liver fat accumulation.
  • FGF21 may help the liver process fats more effectively and support muscle energy use.
PubMed

Fibroblast growth factor 21 attenuates iron overload-induced liver injury and fibrosis by inhibiting ferroptosis.

Animal

Redox biology · 2021

Researchers found that a protein called FGF21 can help protect the liver from damage caused by excess iron. They observed that FGF21 reduces a harmful process called ferroptosis, which contributes to liver injury and fibrosis. This suggests that boosting FGF21 levels might be a promising approach to treat liver diseases related to iron overload.

  • Iron overload increases ferroptosis in liver cells, leading to injury and fibrosis.
  • FGF21 protects liver cells by inhibiting ferroptosis and reducing mitochondrial damage.
  • Enhancing FGF21 levels may offer a new treatment strategy for iron overload-related liver diseases.
PubMed

Fibroblast growth factor 21 (FGF21) alleviates senescence, apoptosis, and extracellular matrix degradation in osteoarthritis via the SIRT1-mTOR signaling pathway.

Animal

Cell death & disease · 2021

Researchers found that fibroblast growth factor 21 (FGF21) helps protect cartilage cells in osteoarthritis by reducing cell death and aging, as well as slowing down the breakdown of important cartilage components. They observed that FGF21 works through a specific cellular pathway, showing promise as a potential treatment for osteoarthritis.

  • FGF21 reduces cell death and aging in cartilage cells.
  • FGF21 slows down the degradation of cartilage components.
  • FGF21 shows potential as a treatment for osteoarthritis.
PubMed

Metabolic Messengers: FGF21.

Review

Nature metabolism · 2021

Researchers observed that FGF21, a hormone involved in regulating metabolism, plays a significant role in managing body weight and metabolic health, particularly in diabetes and obesity. They also found that FGF21 influences how the body uses nutrients and balances energy, highlighting its potential as a therapeutic target.

  • FGF21 helps correct metabolic dysfunction and reduce body weight.
  • It regulates nutrient preference and energy balance.
  • There are still important questions about FGF21's functions that need to be explored.
PubMed

Agonistic β-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions.

Unknown

The Journal of biological chemistry · 2018

Researchers found that a new antibody called 39F7 can mimic the actions of a hormone known as FGF21, which is important for managing metabolism and could help treat conditions like Type 2 diabetes. This antibody works by interacting with a protein called β-Klotho, which is part of the receptor system that FGF21 uses to exert its effects.

  • 39F7 is a high-affinity monoclonal antibody against β-Klotho.
  • The antibody mimics the function of FGF21.
  • 39F7 interacts with β-Klotho in a way that does not compete with FGF21.
PubMed

Track your hormone research in PepStack

Log cycles, set reminders and visualize serum levels.

This page is for informational and research purposes only. All information is based on published scientific literature. Nothing on this page constitutes medical advice or replaces consultation with a qualified healthcare professional.